Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy

doi:10.4253/wjge.v8.i3.128

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9465)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

740

WORD

310

HTML

3545

Tables (1-4)

419

Sum=5014

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

504

Download

986

Sum=1490

Publishing Process of This Article

Item

Count

Browse

1232

Download

1729

Sum=2961

Feb 10, 2016 (publication date) through Jan 17, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Endoscopy

ISSN

1948-5190

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Endosc. Feb 10, 2016; 8(3): 128-142
Published online Feb 10, 2016. doi: 10.4253/wjge.v8.i3.128

Table 3 Prognostic markers in pancreatic ductal adenocarcinoma and cholangiocarcinoma

	Marker	Country	Total patients,n	Marker positive PDAC	Type of dysregulation	Prognostic value, OS months	HR or P value for OS
Pancreatic cancer	SPARC	United States[81]	299	200	Up-regulated	+SPARC: 15 -SPARC: 30	1.89
		Germany[83]	58	58	Up-regulated	+SPARC: 7.6 -SPARC: 10.2	2.23
		Germany[84]	160	95	Up-regulated	+SPARC: 17.9 -SPARC: 30.2	P = 0.006
		Japan[85]	104	104	Up-regulated	Decreased survival	2.92
		Sweden[82]	88	68	Up-regulated	+SPARC: 11.5 -SPARC: 25.3	2.12
	Marker	Country	Total Patients, n	CCA patients, n	Type of dysregulation	Prognostic value	HR (95%CI) or P value for OS
CCA	¹miR-192[130]	Japan	83	51	Up-regulated	Increased LN mets; shorter survival	2.076 (1.004-4.291) P < 0.05 mets
	miR-675-5p[88]	China	72	63	Up-regulated	Shorter survival	2.562 (1.295-4.929)
	miR-652-3p, miR-338-3p[88]	China	72	63	Down-regulated	Increased survival	0.477 (0.247-0.922); 0.498 (0.257-0.966)
	miR-151-3p and miR-126[156]	United States	32	32	Up-regulated and down-regulated, respectively	Increased survival	0.201 (0.043-0.928)
	¹miR-21[46]	Thailand, China	41	32	Up-regulated	Increased LN mets; shorter survival	P < 0.05 OS P = 0.037 mets
	miR-214[157]	China	14	14	Down-regulated	Increased mets	P < 0.05 mets
	miR-373[90]	China	48	48	Down-regulated	Shorter survival	P < 0.05 OS
	Group 1: miR-21, miR-31, miR-223 Group 2: miR-122, miR-145, miR- 146a, miR-200c, miR-221, and miR-222[44]	Greece	179	21	Group 1: Up-regulated Group 2: Down-regulated	None	-
	CYFRA 21-1[18,30]	United Kingdom, Japan	195	137	Up-regulated	Shorter survival	P = 0.001[30] P < 0.01[18]
	EGFR[93,94]	Japan	373	338	Up-regulated	Shorter survival	5.655 (2.72–11.74)[93] 2.67 (1.52-4.69)[94]

¹Liver fluke-associated CCA. PDAC: Pancreatic ductal adenocarcinoma; CCA: Cholangiocarcinoma; mets: Metastases; OS: Overall survival; SPARC: Secreted protein acidic and rich in cysteine; CYFRA 21-1: Cytokeratin 19 fragment; EGFR: Epidermal growth factor receptor; LN: Lymph node.

Citation: Viterbo D, Gausman V, Gonda T. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc 2016; 8(3): 128-142
URL: https://www.wjgnet.com/1948-5190/full/v8/i3/128.htm
DOI: https://dx.doi.org/10.4253/wjge.v8.i3.128